Lawrence W. Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lawrence W. Wu has a total of 310 co-authors. Here are the top co-authors by number of shared publications:
- Meenhard Herlyn
The Wistar Institute, Philadelphia, PA, USA
24 shared publications - Zhi Wei
New Jersey Institute of Technology
22 shared publications Clemens Krepler
21 shared publicationsLynn M. Schuchter
21 shared publications- Gordon Brent Mills
Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
20 shared publications Katrin Sproesser
20 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Springer Nature in EMBO Molecular Medicine
- p. 1-25
Spatial polarization of endothelial ICAM-1 governs T-cell exclusion in melanoma
An immunosuppressive microenvironment limits therapeutic efficacy in melanoma. Beyond T-cell abundance and function, tumor control depends on T-cell access to malignant cells, yet the vascular mechanisms governing T-cell positioning remain poorly defined. Using RNA sequencing of endothelial cells from tumor cores versus peripheries in a mouse melanoma model, we identified intercellular adhesion molecule-1 (ICAM-1) as a candidate regulator of T-cell localization. During tumor growth, T cells shifted from a balanced core-margin distribution to marked exclusion from the core, particularly in T cell-inflamed tumors. This spatial polarization, less evident in other immune subsets, coincided with high expression of lymphocyte function-associated antigen-1 (LFA-1) on T cells. Endothelial ICAM-1 became enriched at the tumor periphery, where vascular integrity was compromised, with increased vascular leakage and reduced pericyte coverage. ICAM-1 blockade restored T-cell infiltration, enhanced effector activity, and delayed growth of immunogenic tumors, and sensitized an immune-refractory tumor to anti-PD-1 blockade. These findings identify endothelial ICAM-1 as a vascular determinant of T-cell positioning and the ICAM-1/LFA-1 axis as a modifiable checkpoint to enhance antitumor immunity and immunotherapy efficacy.
- 19 October 2026
- Published by Springer Nature in EMBO Molecular Medicine
- p. 1-25
Open AccessSpatial polarization of endothelial ICAM-1 governs T-cell exclusion in melanoma
An immunosuppressive microenvironment limits therapeutic efficacy in melanoma. Beyond T-cell abundance and function, tumor control depends on T-cell access to malignant cells, yet the vascular mechanisms governing T-cell positioning remain poorly defined. Using RNA sequencing of endothelial cells from tumor cores versus peripheries in a mouse melanoma model, we identified intercellular adhesion molecule-1 (ICAM-1) as a candidate regulator of T-cell localization. During tumor growth, T cells shifted from a balanced core-margin distribution to marked exclusion from the core, particularly in T cell-inflamed tumors. This spatial polarization, less evident in other immune subsets, coincided with high expression of lymphocyte function-associated antigen-1 (LFA-1) on T cells. Endothelial ICAM-1 became enriched at the tumor periphery, where vascular integrity was compromised, with increased vascular leakage and reduced pericyte coverage. ICAM-1 blockade restored T-cell infiltration, enhanced effector activity, and delayed growth of immunogenic tumors, and sensitized an immune-refractory tumor to anti-PD-1 blockade. These findings identify endothelial ICAM-1 as a vascular determinant of T-cell positioning and the ICAM-1/LFA-1 axis as a modifiable checkpoint to enhance antitumor immunity and immunotherapy efficacy.
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (9)
Comparative Analysis of Potential Clinical Actionability of Genomic Alterations in Early-Onset Versus Later-Onset GI Cancers
PURPOSE: As biomarker-directed therapy increasingly shapes GI oncology, it remains unclear whether early-onset (EO) and later-onset (LO) GI cancers harbor comparable opportunities for clinically actionable targeting. We compared the landscape of potentially actionable genomic alterations in EO versus LO GI cancers using American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange v19.0. METHODS: GI tumor samples were assigned to 10 prespecified tumor groups using OncoTree codes. Samples were annotated with OncoKB therapeutic levels and classified as potentially actionable if they harbored at least one level 1-3B alteration. EO and LO disease were defined as age at sequencing v 78.1%, q < 0.001), esophagogastric (53.3% v 57.9%, q = 0.0097), GI stromal tumor (GIST) (75.1% v 90.9%, q < 0.001), liver (25.4% v 35.4%, q = 0.0021), and pancreatic tumors (82.9% v 90.7%, q < 0.001). In the overall model, LO status was associated with higher odds of potential actionability (odds ratio, 1.39 [95% CI, 1.33 to 1.47]; P < .001). Tumor group-specific associations persisted in colorectal, GIST, liver, and pancreatic tumors after multivariable adjustment. CONCLUSION: Potential clinical actionability differs between EO and LO GI cancers in a tumor lineage-specific manner. Several major EO GI tumor groups appear relatively depleted of potentially actionable alterations, suggesting that the expanding therapeutic reach of precision oncology may not be distributed evenly across age-defined GI cancer populations and underscoring the need for EO-focused biomarker discovery and therapeutic development.
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (9)
Comparative Analysis of Potential Clinical Actionability of Genomic Alterations in Early-Onset Versus Later-Onset GI Cancers
PURPOSE: As biomarker-directed therapy increasingly shapes GI oncology, it remains unclear whether early-onset (EO) and later-onset (LO) GI cancers harbor comparable opportunities for clinically actionable targeting. We compared the landscape of potentially actionable genomic alterations in EO versus LO GI cancers using American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange v19.0. METHODS: GI tumor samples were assigned to 10 prespecified tumor groups using OncoTree codes. Samples were annotated with OncoKB therapeutic levels and classified as potentially actionable if they harbored at least one level 1-3B alteration. EO and LO disease were defined as age at sequencing v 78.1%, q < 0.001), esophagogastric (53.3% v 57.9%, q = 0.0097), GI stromal tumor (GIST) (75.1% v 90.9%, q < 0.001), liver (25.4% v 35.4%, q = 0.0021), and pancreatic tumors (82.9% v 90.7%, q < 0.001). In the overall model, LO status was associated with higher odds of potential actionability (odds ratio, 1.39 [95% CI, 1.33 to 1.47]; P < .001). Tumor group-specific associations persisted in colorectal, GIST, liver, and pancreatic tumors after multivariable adjustment. CONCLUSION: Potential clinical actionability differs between EO and LO GI cancers in a tumor lineage-specific manner. Several major EO GI tumor groups appear relatively depleted of potentially actionable alterations, suggesting that the expanding therapeutic reach of precision oncology may not be distributed evenly across age-defined GI cancer populations and underscoring the need for EO-focused biomarker discovery and therapeutic development.
- Open Access
- 1 May 2026
- Published by AME Publishing Company in Translational Gastroenterology and Hepatology
- Vol. 11, 57
Rethinking the Siewert classification in the era of precision oncology
- 1 May 2026
- Published by AME Publishing Company in Translational Gastroenterology and Hepatology
- Vol. 11, 57
Open AccessRethinking the Siewert classification in the era of precision oncology
- Open Access
PKMYT1 inhibition induces DNA damage and synergizes with immune checkpoint blockade in CCNE1-amplified gastroesophageal adenocarcinoma
Purpose: CCNE1 amplification, found in approximately 10% of gastroesophageal adenocarcinoma (GEA), drives chromosomal instability and is associated with an immune-cold tumor microenvironment. Recent studies suggest that PKMYT1 inhibition is synthetic lethal in CCNE1-amplified cancers; however, its role in GEA is largely uncharacterized. We investigated the therapeutic activity of PKMYT1 inhibition in CCNE1-amplified GEA and its potential combination with immunotherapy. Experimental Design: We evaluated lunresertib (RP-6306), a selective first-in-class PKMYT1 inhibitor, in CCNE1-amplified and wild-type GEA cell lines to define its effects on cell viability, DNA damage, and gene expression changes. To investigate the role of PKMYT1 blockade on immune microenvironment modulation, we used a syngeneic murine model of CCNE1;Trp53-/- GEA xenografts treated with lunresertib, anti-PD-1, or the combination. Results: Lunresertib was selectively cytotoxic in CCNE1-amplified GEA cell lines in cell viability and clonogenic assays. Mechanistically, treatment with lunresertib induced DNA damage, evidence by increased γH2AX expression and DNA micronuclei formation, and activated pro-inflammatory signaling pathways by gene set enrichment analysis. In a CCNE1-amplified GEA murine model, PKMYT1 inhibition promoted T cell infiltration, reduced myeloid cells, and synergized with anti-PD-1 therapy to induce tumor regression. Conclusions: Our results suggest that CCNE1 amplification is a potentially actionable target in GEA and support the development of combination therapeutic strategies utilizing PKMYT1 inhibition and PD-1 blockade.
Open AccessPKMYT1 inhibition induces DNA damage and synergizes with immune checkpoint blockade in CCNE1-amplified gastroesophageal adenocarcinoma
Purpose: CCNE1 amplification, found in approximately 10% of gastroesophageal adenocarcinoma (GEA), drives chromosomal instability and is associated with an immune-cold tumor microenvironment. Recent studies suggest that PKMYT1 inhibition is synthetic lethal in CCNE1-amplified cancers; however, its role in GEA is largely uncharacterized. We investigated the therapeutic activity of PKMYT1 inhibition in CCNE1-amplified GEA and its potential combination with immunotherapy. Experimental Design: We evaluated lunresertib (RP-6306), a selective first-in-class PKMYT1 inhibitor, in CCNE1-amplified and wild-type GEA cell lines to define its effects on cell viability, DNA damage, and gene expression changes. To investigate the role of PKMYT1 blockade on immune microenvironment modulation, we used a syngeneic murine model of CCNE1;Trp53-/- GEA xenografts treated with lunresertib, anti-PD-1, or the combination. Results: Lunresertib was selectively cytotoxic in CCNE1-amplified GEA cell lines in cell viability and clonogenic assays. Mechanistically, treatment with lunresertib induced DNA damage, evidence by increased γH2AX expression and DNA micronuclei formation, and activated pro-inflammatory signaling pathways by gene set enrichment analysis. In a CCNE1-amplified GEA murine model, PKMYT1 inhibition promoted T cell infiltration, reduced myeloid cells, and synergized with anti-PD-1 therapy to induce tumor regression. Conclusions: Our results suggest that CCNE1 amplification is a potentially actionable target in GEA and support the development of combination therapeutic strategies utilizing PKMYT1 inhibition and PD-1 blockade.
- Open Access
- 1 August 2025
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 16 (4) , 1420-1433
Retrospective analysis of Claudin18.2 expression in ethnically diverse patients with gastroesophageal adenocarcinoma
Background: Claudin18.2 (CLDN18.2), a tight junction molecule, is a novel therapeutic target for patients with advanced gastroesophageal adenocarcinoma. Recent phase III trials demonstrated improved survival with the addition of an anti-CLDN18.2 antibody (zolbetuximab) to first-line chemotherapy. However, expression of CLDN18.2 and its association with other biomarkers, especially in racial and ethnic minorities, remains poorly defined. We evaluated CLDN18.2 expression, its association with demographic and clinicopathologic characteristics, and its prognostic potential in a cohort of ethnically diverse patients. Methods: We conducted a single-center retrospective cohort study among patients with gastric, gastroesophageal, and esophageal adenocarcinoma in whom CLDN18.2 immunohistochemistry had been performed. Positivity was defined as moderate-to-strong expression in ≥75% of tumor cells. We extracted demographic and clinicopathologic data from the electronic medical record. Associations with CLDN18.2 were investigated using the t-test and Chi-squared test. Survival curves were calculated using the Kaplan-Meier method and compared using the log-rank test. Results: Among 75 evaluable patients, 32 (42.7%) were CLDN18.2 positive. Mean age was 66.2 years [standard deviation (SD), 13.2 years], 34.7% were female, and 62.7%, 18.7%, and 18.7%, had primary gastric, gastroesophageal junction, and esophageal tumors, respectively. At diagnosis, 32% were metastatic. The cohort was 49.3% White, 12% Black, 8% Asian, 21.3% other, and 9.3% unknown, and 20% identified as Hispanic. By ethnicity, 53.3% of Hispanic patients were CLDN18.2 positive compared to 38.2% of non-Hispanic patients. By race, 37.8% of White, 44.4% of Black, and 50% of Asian patients were CLDN18.2 positive. In univariate analyses, CLDN18.2 positivity was significantly associated with female sex (P=0.002) and human epidermal growth factor receptor 2 (HER2) negativity (P=0.03). TP53 mutations were found in 65.2% of patients with available next-generation sequencing data, but there was no association with CLDN18.2 positivity. CLDN18.2 positivity was also not associated with disease-free survival in patients with localized or locally advanced disease, progression-free survival on first-line therapy in metastatic patients, or overall survival in the total population. Conclusions: This study provides new information on CLDN18.2 expression in an ethnically diverse population and suggests that Hispanic patients may have higher rates of CLDN18.2 positivity than non-Hispanic patients. We also demonstrate the association between CLDN18.2 and female sex and HER2 negativity and lack of association with survival, consistent with published data. Future research should further investigate differences in CLDN18.2 expression and identify subpopulations of patients who may benefit from CLDN18.2-targeted therapies.
- 1 August 2025
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 16 (4) , 1420-1433
Open AccessRetrospective analysis of Claudin18.2 expression in ethnically diverse patients with gastroesophageal adenocarcinoma
Background: Claudin18.2 (CLDN18.2), a tight junction molecule, is a novel therapeutic target for patients with advanced gastroesophageal adenocarcinoma. Recent phase III trials demonstrated improved survival with the addition of an anti-CLDN18.2 antibody (zolbetuximab) to first-line chemotherapy. However, expression of CLDN18.2 and its association with other biomarkers, especially in racial and ethnic minorities, remains poorly defined. We evaluated CLDN18.2 expression, its association with demographic and clinicopathologic characteristics, and its prognostic potential in a cohort of ethnically diverse patients. Methods: We conducted a single-center retrospective cohort study among patients with gastric, gastroesophageal, and esophageal adenocarcinoma in whom CLDN18.2 immunohistochemistry had been performed. Positivity was defined as moderate-to-strong expression in ≥75% of tumor cells. We extracted demographic and clinicopathologic data from the electronic medical record. Associations with CLDN18.2 were investigated using the t-test and Chi-squared test. Survival curves were calculated using the Kaplan-Meier method and compared using the log-rank test. Results: Among 75 evaluable patients, 32 (42.7%) were CLDN18.2 positive. Mean age was 66.2 years [standard deviation (SD), 13.2 years], 34.7% were female, and 62.7%, 18.7%, and 18.7%, had primary gastric, gastroesophageal junction, and esophageal tumors, respectively. At diagnosis, 32% were metastatic. The cohort was 49.3% White, 12% Black, 8% Asian, 21.3% other, and 9.3% unknown, and 20% identified as Hispanic. By ethnicity, 53.3% of Hispanic patients were CLDN18.2 positive compared to 38.2% of non-Hispanic patients. By race, 37.8% of White, 44.4% of Black, and 50% of Asian patients were CLDN18.2 positive. In univariate analyses, CLDN18.2 positivity was significantly associated with female sex (P=0.002) and human epidermal growth factor receptor 2 (HER2) negativity (P=0.03). TP53 mutations were found in 65.2% of patients with available next-generation sequencing data, but there was no association with CLDN18.2 positivity. CLDN18.2 positivity was also not associated with disease-free survival in patients with localized or locally advanced disease, progression-free survival on first-line therapy in metastatic patients, or overall survival in the total population. Conclusions: This study provides new information on CLDN18.2 expression in an ethnically diverse population and suggests that Hispanic patients may have higher rates of CLDN18.2 positivity than non-Hispanic patients. We also demonstrate the association between CLDN18.2 and female sex and HER2 negativity and lack of association with survival, consistent with published data. Future research should further investigate differences in CLDN18.2 expression and identify subpopulations of patients who may benefit from CLDN18.2-targeted therapies.
- 21 July 2025
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
- Vol. 22 (9) , 600-601
Rethinking gastric cancer prevention through an immigrant health lens
- 21 July 2025
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
- Vol. 22 (9) , 600-601
Rethinking gastric cancer prevention through an immigrant health lens
- Open Access
- 4 July 2025
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (7)
Regarding RECIST in retrospective studies
- 4 July 2025
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (7)
Open AccessRegarding RECIST in retrospective studies
- 7 February 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (2) , 267-270
Strengthening Asian/Asian American, Native Hawaiian, and Pacific Islander Leadership in Cancer Research
Summary: Individuals in the United States from Asian and Asian American, Native Hawaiian, and Pacific Islander (AANHPI) backgrounds face a distinct set of cancer-related disparities. In this study, in conjunction with the American Association for Cancer Research Asian/AANHPI Task Force, we highlight the unique disparities faced by AANHPI patients and professionals, and we offer actionable recommendations on how to strengthen AANHPI leadership in cancer research.
- 7 February 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (2) , 267-270
Strengthening Asian/Asian American, Native Hawaiian, and Pacific Islander Leadership in Cancer Research
Summary: Individuals in the United States from Asian and Asian American, Native Hawaiian, and Pacific Islander (AANHPI) backgrounds face a distinct set of cancer-related disparities. In this study, in conjunction with the American Association for Cancer Research Asian/AANHPI Task Force, we highlight the unique disparities faced by AANHPI patients and professionals, and we offer actionable recommendations on how to strengthen AANHPI leadership in cancer research.
- Open Access
- 6 February 2025
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (2)
The complex interplay of antibiotic use and immune checkpoint inhibition
- 6 February 2025
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (2)
Open AccessThe complex interplay of antibiotic use and immune checkpoint inhibition
- Open Access
- 1 January 2024
- Published by SAGE Publications in Journal of Primary Care & Community Health
- Vol. 15
Evaluating the Scope of Services and Monetary Impact of Charity Medical Clinics in North Texas
Introduction/Objectives: The cost of medical services is a major barrier to healthcare accessibility for underserved populations in the United States. Community charity medical clinics help address this disparity by providing free or reduced-cost care for the medically underinsured; however, their economic and public health contributions are unknown. The objective of this study was to evaluate the scope of services and monetary impact of 4 community charity medical clinics in North Texas, with one of the largest medically underinsured populations in the United States. Methods: A cross-sectional study was conducted using electronic health records from 4 clinics serving adults and children in North Texas. Encounters from June 1 to December 31, 2018 completed by with sufficient documentation to assign a level of service were reviewed. There were 3942 encounters identified and 2148 (54.5%) audited. Centers for Medicare and Medicaid Services Evaluation and Management Standards were used to identify level of service provided for each encounter, and their subsequent value was determined based on CMS fee-for-service schedules at the time service was provided. Common conditions managed during these encounters were identified using ICD-10 codes documented with each encounter. Results: The most prevalent diagnoses encountered were hypertension, diabetes, hyperlipidemia, and major depressive disorder. We estimate the total value of services and medications provided for 1 year is between $840 278.30 to $845 737.41. Conclusions: The charity clinics in North Texas provide a significant economic impact through a high level of charity care and a broad scope of services for a vulnerable patient population. The results may be used in the development and implementation of future services to meet the needs of the medically underinsured.
- 1 January 2024
- Published by SAGE Publications in Journal of Primary Care & Community Health
- Vol. 15
Open AccessEvaluating the Scope of Services and Monetary Impact of Charity Medical Clinics in North Texas
Introduction/Objectives: The cost of medical services is a major barrier to healthcare accessibility for underserved populations in the United States. Community charity medical clinics help address this disparity by providing free or reduced-cost care for the medically underinsured; however, their economic and public health contributions are unknown. The objective of this study was to evaluate the scope of services and monetary impact of 4 community charity medical clinics in North Texas, with one of the largest medically underinsured populations in the United States. Methods: A cross-sectional study was conducted using electronic health records from 4 clinics serving adults and children in North Texas. Encounters from June 1 to December 31, 2018 completed by with sufficient documentation to assign a level of service were reviewed. There were 3942 encounters identified and 2148 (54.5%) audited. Centers for Medicare and Medicaid Services Evaluation and Management Standards were used to identify level of service provided for each encounter, and their subsequent value was determined based on CMS fee-for-service schedules at the time service was provided. Common conditions managed during these encounters were identified using ICD-10 codes documented with each encounter. Results: The most prevalent diagnoses encountered were hypertension, diabetes, hyperlipidemia, and major depressive disorder. We estimate the total value of services and medications provided for 1 year is between $840 278.30 to $845 737.41. Conclusions: The charity clinics in North Texas provide a significant economic impact through a high level of charity care and a broad scope of services for a vulnerable patient population. The results may be used in the development and implementation of future services to meet the needs of the medically underinsured.